Convalescent Plasma Therapy: An aspiring option for COVID-19 treatment?


  • Akhil Ranjon Biswas Mymensingh Medical College
  • Md. Mahbubur Rahman National Institute of Cancer Research & Hospital, Dhaka



COVID-19, Convalescent Plasma Therapy


COVID-19 is a cause of life threating severe acute respiratory syndrome (SARS) caused by a novel corona virus named as SARS-Cov-2. Since it has 1st been identified in the city of Wuhan in China in December, 2019, it has spread rapidly all over the world. As it is a newly emerged viral infection and any vaccine or specific therapy yet to be proven as clearly effective, multiple therapeutic option with supportive intent as well as search for specific therapy to combat the virus are under vigorous trial around the world. Convalescent plasma therapy is one such investigational therapeutic option for COVID-19 with hope that neutralizing antibodies present in plasma of persons recovered from COVID-19 would be able to neutralize the virus in infected person.

Author Biographies

Akhil Ranjon Biswas, Mymensingh Medical College

MBBS, FCPS (Haematology), IHTC Fellow (CMC, Vellore)

Professor & Head, Department of Haematology

Mymensingh Medical College, Mymensingh, Bangladesh

Md. Mahbubur Rahman, National Institute of Cancer Research & Hospital, Dhaka

MBBS, FCPS (Haematology), FACP, FRCP

Professor & Head, Department of Haematology, National Institute of Cancer Research & Hospital


Bloom D E, Black S, Rappuoli R. Emerging infectious disease: A proactive approach. PNAS. 2017. 114;16: 4055-4059.

NIH Covid-19 treatment guidelines [Internet] 2020 [Cited 2020, April 25].

Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibody. International Journla of Antimicrobial Agent. 2020. DOI:

Chen L, Xiong J, Bao L, Shi Y, Convalescent plasma as potential therapy for COVID-19, Lancet Infect Dis, epub ahead of print February 27, 2020.

Virus neutralization by antibodies [Internet] July 24, 2009 [Cited 2020, April 25].

Luke TC, Kilbane E M, Jackson J L, Hoffman S L. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med. 2006;145.599-609.

Frame J D, Verbrugge J P, Gill R G, Pinneo L. The use of Lassa fever convalescent plasma in Nigeria. Transactions of The Royal Society of Tropical Medicine and Hygiene. 1978;84;3. 319-324.

Mupapa K, Massamba M, Kibadi K, Kuvula K, et al. Treatment of Ebola hemorrhagic fever with blood transfusion from convalescent patients. The Journal of Infectious diseases. 1999;179(Suppl 1). S18-23.

Cheng Y, Wong R, Soo Y O Y, Wong W S, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005,24. 44-46.

Arabi Y M, Hajeer A H, Luke T, Raviprakash K, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerging Infectious Diseases. 2016;22(9). 1554-1561.

Zhou B. Treatment with convalescent plasma for Influenza (H5N1) infection. New Eng J Med. 2007;354(14). 1450-1451.

Shen C, Wang Z, Zhao F, Yang Y, et al., Treatment of 5 Critically Ill Patients with COVID-19 With Convalescent Plasma. JAMA, epub ahead of print March 27, 2020.

Duan K, Liu B, Li C, Zhang H, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS, epub ahead of print March 18, 2020.

Investigational COVID-19 convalescent plasma: Guidance for Industry. Published online April 13, 2020.

An EU programme of COVID-19 convalescent plasma collection and transfusion: Guidance on collection, testing, processing, storage, distribution and monitored use [Internet] [Cited on 2020, April 25.

Ruggiero H A, Pérez I F, Milani H A, Barri A. Treatment of Argentine Haemorrhagic fever with convalescent’s plasma: 4433 cases. Presse Medicale. 1986;15(45): 2239-2242.

Hung I F N, To K W, Lee C K, Chan K, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinical Infectious Diseases. 2011;52(4):447-456.

Frame J D, Verbrugge G P, Gill R G, Pinneo L. The use of Lassa fever convalescent plasma in Nigeria. Transactions of The Royal Society of Tropical Medicine and Hygiene. 1984;78(3).319–324.

COVID-19 Map-Johns Hopkins Coronovirus Resource Center [Internet] 2020 [Cited July 10, 2020].

Randomised Evaluation of COVID-19 Therapy (RECOVERY). Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. 2020. Available at: Accessed July 11, 2020.

Tang N, Bai H, Chen X, Gong J, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. May 2020;18(5):1094-99.

Li L, Zhang W, Hu Y, Tong X, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life threatening COVID-19: A randomized clinical trial. JAMA. Published Online June 3, 2020. Doi:10.1001/jama. 2020.10044.

DGCI clears clinical trial of plasma therapy in Covid-19 patients. The Hindu Business Line [Internet] April 18,2020 [Cited April 27, 2020].

Rojas M, Rodriguez Y, Monsalve D M, Ampudia Y A, et al. Convalescent Plasma in COVID-19: Possible mechanisms of action. Autoimmunity Review. 19 (2020) 102554.

Institute of Epidemiology, Disease Control and Research (IEDCR) [Internet] July 12, 2020.




How to Cite

Biswas AR, Rahman MM. Convalescent Plasma Therapy: An aspiring option for COVID-19 treatment?. Haematol J Bangladesh [Internet]. 2020Dec.31 [cited 2021Feb.26];4(02):52-6. Available from:



Review Article(s)

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.